Comorbidity and confounding in end-stage renal disease

Kidney International

Volumn 77, Issue 2, 2010, Pages 83-85

  Seliger, Stephen L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMORBIDITY; HEALTH CARE QUALITY; HUMAN; KIDNEY FAILURE; MEDICAID; MEDICARE; NOTE; PATIENT CARE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY;

EID: 73349109469     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.431     Document Type: Note

References (16)

1. Brookhart MA, Wang PS, Solomon DH et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006; 17: 268-275.
2. Bradbury BD, Brookhart MA, Winkelmayer WC et al. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. Am J Kidney Dis 2009; 54: 554-560.
3. Technical Notes on the Standardized Mortality Ratio for the Dialysis Facility Reports. University of Michigan Kidney Epidemiology and Cost Center: Ann Arbor 2009.
4. I. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
5. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
6. Davies SJ, Russell L, Bryan J et al. Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival. Am J Kidney Dis 1995; 26: 353-361.
7. Khan IH, Catto GR, Edward N et al. Influence of coexisting disease on survival on renal-replacement therapy. Lancet 1993; 341: 415-418.
8. Fried L, Bernardini J, Piraino B. Comparison of the Charlson Comorbidity Index and the Davies score as a predictor of outcomes in PD patients. Perit Dial Int 2003; 23: 568-573.
9. van Manen JG, Korevaar JC, Dekker FW et al. How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices. Am J Kidney Dis 2002; 40: 82-89.
10. Liu J, Huang Z, Gilbertson DT et al. An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int 2010; 77: 141-151.
11. Longenecker JC, Coresh J, Klag MJ et al. Validation of comorbid conditions on the end-stage renal disease Medical Evidence Report: the CHOICE Study. J Am Soc Nephrol 2000; 11: 520-529.
12. Seliger SL, Weiss NS, Gillen DL et al. HMG-CoA reduc-tase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61: 297-304.
13. Fellstrom BC, Jardine AG, S chmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
14. II. Wanner C, Krane V, Marz W et al. Ator vastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248. (Pubitemid 41058323)
15. Wolfe RA, Ashby VB, Daugirdas JT et al. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 2000; 35: 8 0-8 8.
16. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.